HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Jong, M. Articles by Krenning, E. P. Search for Related Content PubMed PubMed Citation Articles by de Jong, M. Articles by Krenning, E. P.

Inhomogeneous Localization of Radioactivity in the Human Kidney After Injection of [¹¹¹In-DTPA]Octreotide

¹ Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
² Netherlands Cancer Institute, Amsterdam, The Netherlands
³ Spaarne Hospital, Heemstede, The Netherlands
⁴ Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Bern, Bern, Switzerland

ABSTRACT

In peptide receptor radionuclide therapy (PRRT) using somatostatin analogs labeled with ß-emitters, the radiosensitive kidney is the dose-limiting organ, because of high uptake and retention of the radionuclides after glomerular filtration. Dosimetry calculations are mostly based on the MIRD scheme, assuming homogeneous renal radioactivity distribution. The aim of this study was to reveal the radioactivity distribution in the normal human kidney after intravenous injection of [¹¹¹In-diethylenetriaminepentaacetic acid (DTPA)]octreotide. Methods: Three patients received intravenous injection of [¹¹¹In-DTPA]octreotide before nephrectomy because of renal cancer. Distribution of radioactivity in the human kidney was investigated using SPECT scanning before and ex vivo autoradiography of the kidney after surgery. Results: Radioactivity was localized predominantly in the cortex of the kidney. In the cortex, radioactivity was not distributed homogeneously but formed a striped pattern, with most of the radioactivity centered in the inner cortical zone. Conclusion: These findings show that average dose calculations using the MIRD scheme, assuming homogeneous renal radioactivity distribution, are inadequate to estimate the radiation dose to various parts of the kidney after PRRT. Different effects due to inhomogeneity can be expected from PRRT using radionuclides emitting particles with short particle ranges, for example, Auger electron emitters, -emitters, and low-energy ß-emitters.

Key Words: radionuclide therapy • radiopharmaceuticals • renal • kidney • octreotide • peptide receptor radionuclide therapy

This article has been cited by other articles:

				B. W. Wessels, M. W. Konijnenberg, R. G. Dale, H. B. Breitz, M. Cremonesi, R. F. Meredith, A. J. Green, L. G. Bouchet, A. B. Brill, W. E. Bolch, et al. MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response--Implications for Radionuclide Therapy J. Nucl. Med., November 1, 2008; 49(11): 1884 - 1899. [Abstract] [Full Text] [PDF]

				A. Massaro, S. Cittadin, F. Rossi, L. Rampin, E. Banti, O. Nibale, and D. Rubello Reconstruction Parameters for 111In-Pentetreotide SPECT: Variability with Respect to Body Weight and Body Region J. Nucl. Med. Technol., December 1, 2007; 35(4): 237 - 241. [Abstract] [Full Text] [PDF]

				M. Konijnenberg, M. Melis, R. Valkema, E. Krenning, and M. de Jong Radiation Dose Distribution in Human Kidneys by Octreotides in Peptide Receptor Radionuclide Therapy J. Nucl. Med., January 1, 2007; 48(1): 134 - 142. [Abstract] [Full Text] [PDF]

				M. Cremonesi, M. Ferrari, L. Bodei, G. Tosi, and G. Paganelli Dosimetry in Peptide Radionuclide Receptor Therapy: A Review J. Nucl. Med., September 1, 2006; 47(9): 1467 - 1475. [Abstract] [Full Text] [PDF]

				X. Zhang, W. Cai, F. Cao, E. Schreibmann, Y. Wu, J. C. Wu, L. Xing, and X. Chen 18F-Labeled Bombesin Analogs for Targeting GRP Receptor-Expressing Prostate Cancer J. Nucl. Med., March 1, 2006; 47(3): 492 - 501. [Abstract] [Full Text] [PDF]

				S. M. Verwijnen, E. P. Krenning, R. Valkema, J. G.M. Huijmans, and M. de Jong Oral Versus Intravenous Administration of Lysine: Equal Effectiveness in Reduction of Renal Uptake of [111In-DTPA]Octreotide J. Nucl. Med., December 1, 2005; 46(12): 2057 - 2060. [Abstract] [Full Text] [PDF]

				M. de Jong, R. Barone, E. Krenning, B. Bernard, M. Melis, T. Visser, M. Gekle, T. E. Willnow, S. Walrand, F. Jamar, et al. Megalin Is Essential for Renal Proximal Tubule Reabsorption of 111In-DTPA-Octreotide J. Nucl. Med., October 1, 2005; 46(10): 1696 - 1700. [Abstract] [Full Text] [PDF]

				S. Pauwels, R. Barone, S. Walrand, F. Borson-Chazot, R. Valkema, L. K. Kvols, E. P. Krenning, and F. Jamar Practical Dosimetry of Peptide Receptor Radionuclide Therapy with 90Y-Labeled Somatostatin Analogs J. Nucl. Med., January 1, 2005; 46(1_suppl): 92S - 98S. [Abstract] [Full Text] [PDF]

				R. Barone, F. Borson-Chazot, R. Valkema, S. Walrand, F. Chauvin, L. Gogou, L. K. Kvols, E. P. Krenning, F. Jamar, and S. Pauwels Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose-Effect Relationship J. Nucl. Med., January 1, 2005; 46(1_suppl): 99S - 106S. [Abstract] [Full Text] [PDF]

				S. J. Goldsmith Improving Insight into Radiobiology and Radionuclide Therapy J. Nucl. Med., July 1, 2004; 45(7): 1104 - 1105. [Full Text] [PDF]